Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported a combination of stock vesting and related share sales. On June 1, 2026, restricted stock units converted into 15,249 shares of Teladoc common stock, reflecting compensation awards that vest over time.
On June 2, 2026, Rodrigues sold 5,677 shares of common stock at an average price of $7.627 per share to cover the tax withholding obligation tied to this RSU vesting. After these transactions, he directly held 9,572 shares of Teladoc common stock, while continuing to hold additional restricted stock units that convert to common stock on a one-for-one basis as they vest.
Teladoc Health, Inc. insider Adam C. Vandervoort, the company’s Chief Legal Officer and Secretary, reported equity compensation vesting and related share sales. On June 1, 2026, restricted stock units and performance stock units converted on a one-for-one basis into a total of 14,928 shares of common stock. On June 2, 2026, he sold 7,906 shares of common stock at $7.627 per share to satisfy the tax withholding obligation tied to these vesting awards. Following these transactions, Vandervoort directly owned 110,261 shares of Teladoc common stock.
Teladoc Health, Inc. reported that Carlos Nueno, its President, International, exercised restricted stock units and sold shares primarily to cover taxes. On June 1, 2026, he converted a total of 13,272 restricted stock units into the same number of Teladoc common shares at a conversion price of $0.00 per share, with the units converting on a one-for-one basis into common stock.
On June 2, 2026, Nueno sold 6,196 shares of common stock at an average price of $7.627 per share. A footnote explains these shares were sold to cover the tax withholding obligation related to the vesting of his restricted stock unit awards, indicating a tax-driven disposition rather than a discretionary open-market sale. After these transactions, he directly held 57,671 shares of Teladoc common stock and 13,670 restricted stock units.
The filing also notes earlier equity grants, including 54,675 restricted stock units granted on March 19, 2024 and 104,602 restricted stock units granted on March 1, 2025, both subject to multi-year vesting schedules. These awards illustrate that a significant portion of Nueno’s compensation remains tied to Teladoc’s future share performance through ongoing RSU vesting.
Teladoc Health, Inc. chief executive officer Charles Divita III reported compensation-related stock activity. On June 1, 2026, previously granted restricted stock units and performance stock units converted into a total of 44,242 shares of common stock on a one-for-one basis.
On June 2, 2026, he sold 19,132 shares of common stock at $7.627 per share, with the footnotes stating the shares were sold to cover tax withholding obligations tied to the vesting of these awards. After the transactions, he directly owned 389,894 common shares.
Teladoc Health Chief Accounting Officer Joseph Ronald Catapano reported routine equity compensation activity. On June 1, 2026, he exercised restricted stock units and performance stock units that converted into a total of 872 shares of common stock at $0.00 per share. On June 2, 2026, 284 shares of common stock were sold at $7.627 per share to cover tax withholding obligations related to these vestings. After these transactions, he directly holds 10,837 shares of Teladoc Health common stock.
Teladoc Health President U.S. Group Health Kelly Bliss reported routine equity compensation activity. On June 1, 2026, she exercised performance and restricted stock units that converted into a total of 15,310 shares of common stock at a conversion price of $0.00 per share.
On June 2, 2026, she sold 7,679 common shares at $7.627 per share to cover the tax withholding obligation tied to these vestings, according to the footnotes. After these transactions, she directly owned 92,378 Teladoc shares, indicating a net increase in her equity position.
Teladoc Health (TDOC) filed a Form 144 notice to sell 9,572 shares of Common Stock tied to restricted stock vesting on 06/01/2026. The filing lists those 9,572 shares as "Restricted Stock Vesting" with the issuer indicated as the source and a compensation origin.
The excerpt also shows prior sales by Fernando Madeira Rodrigues: 25,086 shares sold on 03/03/2026 for $124,972.91, and 5,677 shares sold on 06/02/2026 for $43,298.49. A brokerage line references Fidelity Brokerage Services LLC and $70,832.80 on 06/03/2026.
Tedious, Inc. (TDOC) filing shows a proposed insider sale and recent dispositions. The filing lists 19,132 shares of Common Stock as securities to be sold in connection with Restricted Stock Vesting on 06/01/2026. The filing also discloses prior sales of 50,145 shares on 03/02/2026 for $256,576.92 and 27,731 shares on 03/11/2026 for $152,251.51 by Charles Divita.
The filing is a Form 144 notice reporting a proposed sale of 5,677 shares of Common Stock tied to restricted stock vesting on 06/01/2026. It also lists prior reported dispositions by Fernando Madeira Rodrigues of 16,314 shares on 03/02/2026 and 25,086 shares on 03/03/2026, with proceeds shown as $83,473.84 and $124,972.91, respectively.
Adam Vandervoort submitted a Form 144 reporting an intended sale of 7,906 shares of Common stock following a restricted stock vesting on 06/01/2026. The filing also discloses a prior sale of 27,083 shares on 03/02/2026.